Abstract:Objectives Idiopathic inflammatory myopathy (IIM) frequently coexists with interstitial pneumonia (IP) and is commonly the initial or sole manifestation accompanied by positive myositis-specific autoantibodies (MSAs), even in the absence of meeting diagnostic criteria. This study aims to evaluate the proportion of progressive pulmonary fibrosis (PPF) and identify potential predictors influencing the progression of pulmonary fibrosis in patients with MSA-IP. Methods This descriptive study employed a retrospective cohort design, enrolling patients diagnosed with interstitial pneumonia and positive MSAs at Beijing Chao-Yang Hospital in a sequential manner. Clinical data were systematically collected from the patients’ medical records during regular follow-up visits conducted every 3 to 6 months. Cox regression analysis was utilized to identify independent predictors of PPF in patients with positive MSAs and interstitial pneumonia. Results A total of 307 patients were included in the study, with 30.6% of them developing PPF during a median follow-up period of 22 months. Kaplan–Meier survival curves demonstrated a significantly lower survival in the PPF patients compared to the non-PPF patients (median 11.6 months vs. 31 months, p = 0.000). An acute/subacute onset of interstitial pneumonia (HR 3.231, 95%CI 1.936–5.392, p = 0.000), lower diffusing capacity of the lungs for carbon monoxide (DLCO) % predicted (HR 6.435, 95%CI 4.072–10.017, p = 0.001), and the presence of diffuse alveolar damage (DAD) on high-resolution computed tomography (HRCT) (HR 8.679, 95%CI 1.974–38.157, p = 0.004) emerged as independent predictors of PPF. Notably, the implementation of triple therapy comprising glucocorticoids, immunosuppressants, and antifibrotic drugs was associated with a reduced risk of developing PPF (HR 0.322, 95%CI 0.115–0.899, p = 0.031). Conclusion Approximately 30.6% of patients with MSA-IP may develop PPF within the follow-up period. Patients presenting with an acute/subacute onset of interstitial pneumonia, lower predicted DLCO SB% and evidence of DAD on HRCT are more susceptible to developing PPF. Conversely, the administration of triple therapy appears to serve as a protective factor against the development of PPF in patients with MSA-IP.

Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease

Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact

Predictors and prognosis of pulmonary hypertension complicating interstitial lung disease in systemic sclerosis

Proportion and predictors of FVC decline in patients with interstitial lung disease

Prevalence and risk factors of progressive pulmonary fibrosis(PPF) in patients with Interstitial Lung Disease(ILD) in a tertiary care center in India

Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis

Association between acute exacerbation and progressive pulmonary fibrosis in interstitial lung disease: a retrospective cohort study

Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions

Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis

A study on the prevalence and prognosis of progressive pulmonary fibrosis: A retrospective observational study

Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease

Favorable long term effects of intensified immunosuppression combined with therapeutic plasma exchange in patients with early-onset progressive systemic sclerosis-related interstitial lung disease

Characterisation of incident interstitial lung disease in late systemic sclerosis

Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)

Predictive factors for interstitial lung disease progression in a Singapore systemic sclerosis cohort: a multicentre study

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

Progressive pulmonary fibrosis in myositis-specific antibody-positive interstitial pneumonia: a retrospective cohort study

Progressive pulmonary fibrosis: an expert group consensus statement

Predicting progressive phenotype in patients with fibrotic interstitial lung disease